文献速递前列腺癌

血液与尿液前列腺癌生物标志物:用于检测与治疗决策的新型生物标志物综述与比较

Blood-based and urinary prostate cancer biomarkers: a review and comparison of novel biomarkers for detection and treatment decisions.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2016-12-06

本文综述了用于前列腺癌检测、随访和治疗决策的新型血液与尿液生物标志物模型,包括PHI、PCA3、4K、TMPRSS2-ERG、ExoDx Prostate Intelliscore、SelectMDx和Mi-Prostate score。其中PHI和PCA3获美国食品药品监督管理局批准用于前列腺癌诊断。比较研究显示两者在预测前列腺活检前列腺癌方面结果相互矛盾,PHI和PCA3均能预测根治性前列腺切除术标本的病理特征,PHI可预测精囊侵犯而PCA3可预测多灶性,有证据表明PHI在预测主动监测人群显著性前列腺癌方面优于PCA3。

要点

  • PHI和PCA3是两种获美国食品药品监督管理局批准用于前列腺癌诊断的生物标志物。
  • PHI与PCA3在预测初次和重复前列腺活检前列腺癌方面研究结果相互矛盾。
  • 有证据表明PHI在预测主动监测人群显著性前列腺癌方面优于PCA3。

核心结论

  • 未来研究应聚焦于对有前景的液体生物标志物或模型进行独立验证,以及生物标志物之间的前瞻性比较。

研究设计与样本

  • 综述,讨论用于前列腺癌检测、随访和治疗决策的新型血液与尿液生物标志物模型,并对已发表的比较PHI与PCA3的研究进行概述。

主要发现

  • PHI与PCA3在预测初次和重复前列腺活检前列腺癌方面的研究结果相互矛盾。
  • PHI和PCA3均能预测根治性前列腺切除术标本的病理特征,如肿瘤体积和Gleason评分。
  • 仅PHI可预测精囊侵犯,仅PCA3可预测多灶性。
  • 有证据表明PHI在预测主动监测人群显著性前列腺癌方面优于PCA3。

关键数值与推荐

  • PHI和PCA3是两种获美国食品药品监督管理局批准用于前列腺癌诊断的生物标志物。
  • 针对这些新型液体生物标志物和/或模型的头对头研究很少。

局限性

  • 针对这些新型液体生物标志物和/或模型的头对头研究很少。
  • PHI与PCA3在预测初次和重复前列腺活检前列腺癌方面的研究结果相互矛盾。
  • 未来研究应聚焦于对有前景的液体生物标志物或模型进行独立验证,以及生物标志物之间的前瞻性比较。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The diagnosis of prostate cancer (PCa) is currently based on serum PSA testing and/or abnormal digital rectal examination and histopathologic evaluation of prostate biopsies. The main drawback of PSA testing is the lack of specificity for PCa. To improve early detection of PCa more specific biomarkers are needed. In the past few years, many new promising biomarkers have been identified; however, to date, only a few have reached clinical practice. METHODS: In this review, we discuss new blood-based and urinary biomarker models that are promising for usage in PCa detection, follow-up and treatment decision-making. These include Prostate Health Index (PHI), prostate cancer antigen 3 (PCA3), four-kallikrein panel (4K), transmembrane protease serine 2-ERG (TMPRSS2-ERG), ExoDx Prostate Intelliscore, SelectMDx and the Mi-Prostate score. Only few head-to-head studies are available for these new fluid-based biomarkers and/or models. The blood-based PHI and urinary PCA3 are two US Food and Drug Administration-approved biomarkers for diagnosis of PCa. In the second part of this review, we give an overview of published studies comparing these two available biomarkers for prediction of (1) PCa upon prostate biopsy, (2) pathological features in radical prostatectomy specimen and (3) significant PCa in patients eligible for active surveillance. RESULTS: Studies show opposing results in comparison of PHI with PCA3 for prediction of PCa upon initial and repeat prostate biopsy. PHI and PCA3 are able to predict pathological findings on radical prostatectomy specimen, such as tumor volume and Gleason score. Only PHI could predict seminal vesicle invasion and only PCA3 could predict multifocality. There is some evidence that PHI outperforms PCA3 in predicting significant PCa in an active surveillance population. CONCLUSIONS: Future research should focus on independent validation of promising fluid-based biomarkers/models, and prospective comparison of biomarkers with each other.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Hendriks RJ, van Oort IM, Schalken JA, et al. Blood-based and urinary prostate cancer biomarkers: a review and comparison of novel biomarkers for detection and treatment decisions. Prostate Cancer Prostatic Dis. 2016. PMID: 27922627. doi:10.1038/pcan.2016.59

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。